6EY7

Human cytomegalovirus terminase nuclease domain, Mn soaked, inhibitor bound

6EY7 の概要

• エントリーDOI: 10.2210/pdb6ey7/pdb
• 分子名称: UL89 HCMV terminase, MANGANESE (II) ION, 4-[(4-fluorophenyl)methyl-methyl-amino]-2,4-bis(oxidanylidene)butanoic acid, ... (5 entities in total)
• 機能のキーワード: cytomegalovirus, ul89, terminase, inhibitors, drug design, raltegravir, viral protein
• 由来する生物種: Human herpesvirus 5 strain AD169
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 128869.29

構造登録者

Bongarzone, S.,Nadal, M.,Kaczmarska, Z.,Machon, C.,Alvarez, M.,Albericio, F.,Coll, M. (登録日: 2017-11-10, 公開日: 2018-10-03, 最終更新日: 2024-01-17)

主引用文献

Bongarzone, S.,Nadal, M.,Kaczmarska, Z.,Machon, C.,Alvarez, M.,Albericio, F.,Coll, M.
Structure-Driven Discovery of alpha , gamma-Diketoacid Inhibitors Against UL89 Herpesvirus Terminase.
Acs Omega, 3:8497-8505, 2018

PubMed Abstract: Human cytomegalovirus (HCMV) is an opportunistic pathogen causing a variety of severe viral infections, including irreversible congenital disabilities. Nowadays, HCMV infection is treated by inhibiting the viral DNA polymerase. However, DNA polymerase inhibitors have several drawbacks. An alternative strategy is to use compounds against the packaging machinery or terminase complex, which is essential for viral replication. Our discovery that raltegravir (), a human immunodeficiency virus drug, inhibits the nuclease function of UL89, one of the protein subunits of the complex, prompted us to further develop terminase inhibitors. On the basis of the structure of , a library of diketoacid (α,γ-DKA and β,δ-DKA) derivatives were synthesized and tested for UL89-C nuclease activity. The mode of action of α,γ-DKA derivatives on the UL89 active site was elucidated by using X-ray crystallography, molecular docking, and in vitro experiments. Our studies identified α,γ-DKA derivative able to inhibit UL89 in vitro in the low micromolar range, making an optimal candidate for further development and virus-infected cell assay.

PubMed: 31458978
DOI: 10.1021/acsomega.8b01472

実験手法

X-RAY DIFFRACTION (2.9 Å)